Noura AlDhaheri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Noura AlDhaheri has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Bassam R. Ali
Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
5 shared publications - Mohd Saberi Mohamad
Department of Genetics and Genomics, College of Medicine and Health Sciences Al Ain Abu Dhabi 17666 United Arab Emirates University
4 shared publications - Rahaf M. Ahmad
Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University , Al Ain, P.O. Box 15551, Sheikh Khalifa Bin Zayed Street, Al Maqam District, Abu Dhabi Emirate
3 shared publications - Fatma Al Jasmi
Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain 15551, United Arab Emirates
2 shared publications - Fernando Scaglia
Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
2 shared publications - Sarah H. Elsea
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Delineation of the molecular spectrum of ocular genetic disorders in the United Arab Emirates
- 11 August 2026
- Published by Springer Nature in Human Genomics
- Vol. 20 (1)
Open AccessDelineation of the molecular spectrum of ocular genetic disorders in the United Arab Emirates
- Open Access
- 20 May 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
AI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework
Breast cancer's genomic heterogeneity complicates drug discovery, making repurposing an attractive but challenging strategy. Advances in artificial intelligence now enable integration of multi-omics data to reveal drug-gene-disease relationships and generate subtype-specific repurposing hypotheses. In this Review, we examine AI-driven computational approaches from signature-based to multi-modal frameworks and propose an integrated interpretability-driven framework linking mechanistic validation with clinical translation toward more transparent and actionable precision oncology.
- 20 May 2026
- Published by Springer Nature in npj Genomic Medicine
- Vol. 11 (1)
Open AccessAI-genomics synergy for drug repurposing in breast cancer: an interpretability-driven framework
Breast cancer's genomic heterogeneity complicates drug discovery, making repurposing an attractive but challenging strategy. Advances in artificial intelligence now enable integration of multi-omics data to reveal drug-gene-disease relationships and generate subtype-specific repurposing hypotheses. In this Review, we examine AI-driven computational approaches from signature-based to multi-modal frameworks and propose an integrated interpretability-driven framework linking mechanistic validation with clinical translation toward more transparent and actionable precision oncology.
- Open Access
- 1 November 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (6)
Precision in prediction: tailoring machine learning models for breast cancer missense variants pathogenicity prediction
Accurate classification of genetic variants is critical for precision medicine, particularly hereditary diseases such as breast cancer. However, widely used tools like MutPred and Combined Annotation Dependent Depletion (CADD) offer genome-wide pathogenicity predictions that often overlook disease-specific variant behavior, limiting their clinical utility. This study addresses that gap by training and benchmarking nine machine learning (ML) models-including ensemble and baseline classifiers-on a breast cancer gene-specific dataset rich in conservation scores, functional annotations, and allele frequency features. Among all models, the Extra Trees model achieved the highest performance, with an accuracy of 0.999 and a 95% confidence interval of (0.998–1.000). recursive feature elimination identified the most informative genomic features, enhancing model efficiency. To ensure clinical transparency, we applied interpretability techniques including Local Interpretable Model-Agnostic Explanations and permutation feature importance, which highlighted the key drivers of each prediction. The calibration curve further confirmed the reliability of predicted probabilities, supporting their potential use in clinical decision-making. On an independent ClinGen dataset, Extra Trees achieved 99.1% accuracy and outperformed widely used predictors confirming its robustness and clinical applicability. This is the first comprehensive benchmarking study to apply ML models specifically to breast cancer-related missense variants using disease-gene-specific training data and integrated interpretability. Our results show that disease-specific ML approaches outperform general predictors, offering improved reliability, transparency, and relevance to clinical genomics. By bridging the gap between broad genome-wide tools and tailored clinical prediction, this study lays the foundation for implementing ML-driven pathogenicity prediction in breast cancer diagnostics and precision medicine, with potential expansion to other disease contexts.
- 1 November 2025
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 26 (6)
Open AccessPrecision in prediction: tailoring machine learning models for breast cancer missense variants pathogenicity prediction
Accurate classification of genetic variants is critical for precision medicine, particularly hereditary diseases such as breast cancer. However, widely used tools like MutPred and Combined Annotation Dependent Depletion (CADD) offer genome-wide pathogenicity predictions that often overlook disease-specific variant behavior, limiting their clinical utility. This study addresses that gap by training and benchmarking nine machine learning (ML) models-including ensemble and baseline classifiers-on a breast cancer gene-specific dataset rich in conservation scores, functional annotations, and allele frequency features. Among all models, the Extra Trees model achieved the highest performance, with an accuracy of 0.999 and a 95% confidence interval of (0.998–1.000). recursive feature elimination identified the most informative genomic features, enhancing model efficiency. To ensure clinical transparency, we applied interpretability techniques including Local Interpretable Model-Agnostic Explanations and permutation feature importance, which highlighted the key drivers of each prediction. The calibration curve further confirmed the reliability of predicted probabilities, supporting their potential use in clinical decision-making. On an independent ClinGen dataset, Extra Trees achieved 99.1% accuracy and outperformed widely used predictors confirming its robustness and clinical applicability. This is the first comprehensive benchmarking study to apply ML models specifically to breast cancer-related missense variants using disease-gene-specific training data and integrated interpretability. Our results show that disease-specific ML approaches outperform general predictors, offering improved reliability, transparency, and relevance to clinical genomics. By bridging the gap between broad genome-wide tools and tailored clinical prediction, this study lays the foundation for implementing ML-driven pathogenicity prediction in breast cancer diagnostics and precision medicine, with potential expansion to other disease contexts.
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 27, 4668-4681
Leveraging AutoML to optimize dataset selection for improved breast cancer variants pathogenicity prediction
Breast cancer (BC) remains one of the most prevalent and lethal malignancies worldwide, with its onset shaped by complex interactions between germline predispositions, environmental exposures, and accumulated somatic mutations. Accurate prediction of variant pathogenicity is essential for identifying high-risk individuals, guiding early detection, and tailoring treatment strategies. However, existing computational tools often lack disease-specific training and fail to generalize across diverse variant datasets. To address this gap, we systematically benchmarked the predictive utility of four distinct variant datasets using three Automated Machine Learning (AutoML) frameworks-TPOT, H2O AutoML, and MLJAR. Our goal was to evaluate how dataset composition influences classification performance and to identify the optimal dataset for BC-specific pathogenicity prediction. Among the datasets evaluated, Dataset-2-curated from both cancer-specific and non-cancer databases, consistently yielded the highest predictive performance across all frameworks. H2O AutoML achieved a peak accuracy of 99.99 %, while TPOT and MLJAR also exhibited robust generalization on this dataset. Feature importance analyses revealed strong convergence across frameworks, highlighting conservation scores and pathogenicity metrics as dominant predictors. Interpretability techniques including SHAP, permutation importance, and LIME further validated the biological relevance and transparency of the models. This study presents a scalable, interpretable AutoML benchmarking framework tailored to the clinical prioritization of BC variants. By demonstrating the superiority of cancer-specific, disease-relevant datasets, our findings underscore the critical importance of thoughtful dataset design in machine learning pipelines for genomic medicine. Beyond BC, this framework is readily transferable to other genetic disorders, providing a foundational tool for precision diagnostics and the advancement of personalized oncology.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Computational and Structural Biotechnology Journal
- Vol. 27, 4668-4681
Open AccessLeveraging AutoML to optimize dataset selection for improved breast cancer variants pathogenicity prediction
Breast cancer (BC) remains one of the most prevalent and lethal malignancies worldwide, with its onset shaped by complex interactions between germline predispositions, environmental exposures, and accumulated somatic mutations. Accurate prediction of variant pathogenicity is essential for identifying high-risk individuals, guiding early detection, and tailoring treatment strategies. However, existing computational tools often lack disease-specific training and fail to generalize across diverse variant datasets. To address this gap, we systematically benchmarked the predictive utility of four distinct variant datasets using three Automated Machine Learning (AutoML) frameworks-TPOT, H2O AutoML, and MLJAR. Our goal was to evaluate how dataset composition influences classification performance and to identify the optimal dataset for BC-specific pathogenicity prediction. Among the datasets evaluated, Dataset-2-curated from both cancer-specific and non-cancer databases, consistently yielded the highest predictive performance across all frameworks. H2O AutoML achieved a peak accuracy of 99.99 %, while TPOT and MLJAR also exhibited robust generalization on this dataset. Feature importance analyses revealed strong convergence across frameworks, highlighting conservation scores and pathogenicity metrics as dominant predictors. Interpretability techniques including SHAP, permutation importance, and LIME further validated the biological relevance and transparency of the models. This study presents a scalable, interpretable AutoML benchmarking framework tailored to the clinical prioritization of BC variants. By demonstrating the superiority of cancer-specific, disease-relevant datasets, our findings underscore the critical importance of thoughtful dataset design in machine learning pipelines for genomic medicine. Beyond BC, this framework is readily transferable to other genetic disorders, providing a foundational tool for precision diagnostics and the advancement of personalized oncology.
- Open Access
- 11 September 2024
- Published by Springer Nature in Human Genomics
- Vol. 18 (1) , 1-16
AI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes
Single nucleotide variants (SNVs) can exert substantial and extremely variable impacts on various cellular functions, making accurate predictions of their consequences challenging, albeit crucial especially in clinical settings such as in oncology. Laboratory-based experimental methods for assessing these effects are time-consuming and often impractical, highlighting the importance of in-silico tools for variant impact prediction. However, the performance metrics of currently available tools on breast cancer missense variants from benchmarking databases have not been thoroughly investigated, creating a knowledge gap in the accurate prediction of pathogenicity. In this study, the benchmarking datasets ClinVar and HGMD were used to evaluate 21 Artificial Intelligence (AI)-derived in-silico tools. Missense variants in breast cancer genes were extracted from ClinVar and HGMD professional v2023.1. The HGMD dataset focused on pathogenic variants only, to ensure balance, benign variants for the same genes were included from the ClinVar database. Interestingly, our analysis of both datasets revealed variants across genes with varying penetrance levels like low and moderate in addition to high, reinforcing the value of disease-specific tools. The top-performing tools on ClinVar dataset identified were MutPred (Accuracy = 0.73), Meta-RNN (Accuracy = 0.72), ClinPred (Accuracy = 0.71), Meta-SVM, REVEL, and Fathmm-XF (Accuracy = 0.70). While on HGMD dataset they were ClinPred (Accuracy = 0.72), MetaRNN (Accuracy = 0.71), CADD (Accuracy = 0.69), Fathmm-MKL (Accuracy = 0.68), and Fathmm-XF (Accuracy = 0.67). These findings offer clinicians and researchers valuable insights for selecting, improving, and developing effective in-silico tools for breast cancer pathogenicity prediction. Bridging this knowledge gap contributes to advancing precision medicine and enhancing diagnostic and therapeutic approaches for breast cancer patients with potential implications for other conditions.
- 11 September 2024
- Published by Springer Nature in Human Genomics
- Vol. 18 (1) , 1-16
Open AccessAI-derived comparative assessment of the performance of pathogenicity prediction tools on missense variants of breast cancer genes
Single nucleotide variants (SNVs) can exert substantial and extremely variable impacts on various cellular functions, making accurate predictions of their consequences challenging, albeit crucial especially in clinical settings such as in oncology. Laboratory-based experimental methods for assessing these effects are time-consuming and often impractical, highlighting the importance of in-silico tools for variant impact prediction. However, the performance metrics of currently available tools on breast cancer missense variants from benchmarking databases have not been thoroughly investigated, creating a knowledge gap in the accurate prediction of pathogenicity. In this study, the benchmarking datasets ClinVar and HGMD were used to evaluate 21 Artificial Intelligence (AI)-derived in-silico tools. Missense variants in breast cancer genes were extracted from ClinVar and HGMD professional v2023.1. The HGMD dataset focused on pathogenic variants only, to ensure balance, benign variants for the same genes were included from the ClinVar database. Interestingly, our analysis of both datasets revealed variants across genes with varying penetrance levels like low and moderate in addition to high, reinforcing the value of disease-specific tools. The top-performing tools on ClinVar dataset identified were MutPred (Accuracy = 0.73), Meta-RNN (Accuracy = 0.72), ClinPred (Accuracy = 0.71), Meta-SVM, REVEL, and Fathmm-XF (Accuracy = 0.70). While on HGMD dataset they were ClinPred (Accuracy = 0.72), MetaRNN (Accuracy = 0.71), CADD (Accuracy = 0.69), Fathmm-MKL (Accuracy = 0.68), and Fathmm-XF (Accuracy = 0.67). These findings offer clinicians and researchers valuable insights for selecting, improving, and developing effective in-silico tools for breast cancer pathogenicity prediction. Bridging this knowledge gap contributes to advancing precision medicine and enhancing diagnostic and therapeutic approaches for breast cancer patients with potential implications for other conditions.
- Open Access
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
A review of genetic variant databases and machine learning tools for predicting the pathogenicity of breast cancer
Studies continue to uncover contributing risk factors for breast cancer (BC) development including genetic variants. Advances in machine learning and big data generated from genetic sequencing can now be used for predicting BC pathogenicity. However, it is unclear which tool developed for pathogenicity prediction is most suited for predicting the impact and pathogenicity of variant effects. A significant challenge is to determine the most suitable data source for each tool since different tools can yield different prediction results with different data inputs. To this end, this work reviews genetic variant databases and tools used specifically for the prediction of BC pathogenicity. We provide a description of existing genetic variants databases and, where appropriate, the diseases for which they have been established. Through example, we illustrate how they can be used for prediction of BC pathogenicity and discuss their associated advantages and disadvantages. We conclude that the tools that are specialized by training on multiple diverse datasets from different databases for the same disease have enhanced accuracy and specificity and are thereby more helpful to the clinicians in predicting and diagnosing BC as early as possible.
- 22 November 2023
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 25 (1)
Open AccessA review of genetic variant databases and machine learning tools for predicting the pathogenicity of breast cancer
Studies continue to uncover contributing risk factors for breast cancer (BC) development including genetic variants. Advances in machine learning and big data generated from genetic sequencing can now be used for predicting BC pathogenicity. However, it is unclear which tool developed for pathogenicity prediction is most suited for predicting the impact and pathogenicity of variant effects. A significant challenge is to determine the most suitable data source for each tool since different tools can yield different prediction results with different data inputs. To this end, this work reviews genetic variant databases and tools used specifically for the prediction of BC pathogenicity. We provide a description of existing genetic variants databases and, where appropriate, the diseases for which they have been established. Through example, we illustrate how they can be used for prediction of BC pathogenicity and discuss their associated advantages and disadvantages. We conclude that the tools that are specialized by training on multiple diverse datasets from different databases for the same disease have enhanced accuracy and specificity and are thereby more helpful to the clinicians in predicting and diagnosing BC as early as possible.
- 10 August 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (5) , 573-600
Spectrum of neuro‐genetic disorders in the United Arab Emirates national population
Clinical and molecular characterization of neuro‐genetic disorders among UAE national patients seen in the Genetic Clinic at Tawam hospital over a period of 3 years. A retrospective chart review of all Emirati patients assessed by clinical geneticists due to neuro‐genetic disorders including global developmental delay, ASD, ID, ADHD, and epilepsy in combination with abnormalities of other organ systems. Each patient had proper assessment including detailed history, three‐generation family history, developmental history and detailed physical examination looking for other system involvement. Hearing test and ophthalmological examination were performed when needed. Magnetic resonance imaging (MRI) of the brain, echocardiogram, and renal ultrasound were pursued as indicated. Detailed psychological evaluation and psychometric assessment were done when indicated. The review was done for a period between January 2018 and December 2020. Genetic investigations included chromosome karyotype, FISH study, metabolic/biochemical tests, chromosome microarray, gene sequencing, targeted mutation testing, trio whole exome and trio genome sequencing. A total of 644 patients with developmental delay, ID, learning difficulty, ASD, ADHD, or NNDs, were seen in genetic clinic from January 2018 to December 2020. A total of 506 patients were included in this review, all completed the genetic evaluations during the study period. There were 398 (61.8%) males and 246 (38.2%) females, with a ratio of 1.6:1. Positive family history of NDD was documented in 132 families, while 115 families had negative history and family history was unknown/unclear in the remaining. Fifty seven (11.26% [57/506]) patients had positive microarray results. Hundred ninety seven (38.9% [197/506]) patients had positive molecular testing. Genetic disorders were found in 133 (67.5% [133/197]) and inborn errors of metabolism were found in 42 (21.3% [42/197]). Consanguinity was documented in 139 patients with positive molecular diagnoses (139/197, 70.5%). Sixty nine (35% [69/197]) patients had autosomal dominant disorders, majority were De Novo (84%). Ninety‐five (48% [95/197]) patients had autosomal recessive diseases, 40 mutations involved inborn errors of metabolism and 50 mutations involved genetic disorders. Pathogenic variants causing both autosomal dominant and recessive disorders were found in 98 patients (49.7% [98/197]), likely pathogenic variants causing both autosomal dominant and recessive disorders were found in 66 patients (33.5% [66/197]). X‐linked related disorders were found in 10 patients (5% [10/197]). Mitochondrial mutation was found in one patient. Novel mutations were found in 76 patients (76/197 i.e., 38.56%). Twenty two patients had variants of unknown significant. The remaining 252 studied patients (252/506 i.e., 49.8%), remained undiagnosed. This study shows that neuro‐genetic disorders in the UAE are very heterogeneous at clinical and molecular levels. Using microarray, WES and WGS a diagnosis was reached in 50% of the patients while no diagnosis was reached in other half of the studied patients. It is possible that some mutations were missed by WGS and WES. However, it is also possible that many of disorders in UAE population are novel and the causative mutation is not yet discovered. More researches need to be done in this population to uncover the molecular basis of these disorders.
- 10 August 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (5) , 573-600
Spectrum of neuro‐genetic disorders in the United Arab Emirates national population
Clinical and molecular characterization of neuro‐genetic disorders among UAE national patients seen in the Genetic Clinic at Tawam hospital over a period of 3 years. A retrospective chart review of all Emirati patients assessed by clinical geneticists due to neuro‐genetic disorders including global developmental delay, ASD, ID, ADHD, and epilepsy in combination with abnormalities of other organ systems. Each patient had proper assessment including detailed history, three‐generation family history, developmental history and detailed physical examination looking for other system involvement. Hearing test and ophthalmological examination were performed when needed. Magnetic resonance imaging (MRI) of the brain, echocardiogram, and renal ultrasound were pursued as indicated. Detailed psychological evaluation and psychometric assessment were done when indicated. The review was done for a period between January 2018 and December 2020. Genetic investigations included chromosome karyotype, FISH study, metabolic/biochemical tests, chromosome microarray, gene sequencing, targeted mutation testing, trio whole exome and trio genome sequencing. A total of 644 patients with developmental delay, ID, learning difficulty, ASD, ADHD, or NNDs, were seen in genetic clinic from January 2018 to December 2020. A total of 506 patients were included in this review, all completed the genetic evaluations during the study period. There were 398 (61.8%) males and 246 (38.2%) females, with a ratio of 1.6:1. Positive family history of NDD was documented in 132 families, while 115 families had negative history and family history was unknown/unclear in the remaining. Fifty seven (11.26% [57/506]) patients had positive microarray results. Hundred ninety seven (38.9% [197/506]) patients had positive molecular testing. Genetic disorders were found in 133 (67.5% [133/197]) and inborn errors of metabolism were found in 42 (21.3% [42/197]). Consanguinity was documented in 139 patients with positive molecular diagnoses (139/197, 70.5%). Sixty nine (35% [69/197]) patients had autosomal dominant disorders, majority were De Novo (84%). Ninety‐five (48% [95/197]) patients had autosomal recessive diseases, 40 mutations involved inborn errors of metabolism and 50 mutations involved genetic disorders. Pathogenic variants causing both autosomal dominant and recessive disorders were found in 98 patients (49.7% [98/197]), likely pathogenic variants causing both autosomal dominant and recessive disorders were found in 66 patients (33.5% [66/197]). X‐linked related disorders were found in 10 patients (5% [10/197]). Mitochondrial mutation was found in one patient. Novel mutations were found in 76 patients (76/197 i.e., 38.56%). Twenty two patients had variants of unknown significant. The remaining 252 studied patients (252/506 i.e., 49.8%), remained undiagnosed. This study shows that neuro‐genetic disorders in the UAE are very heterogeneous at clinical and molecular levels. Using microarray, WES and WGS a diagnosis was reached in 50% of the patients while no diagnosis was reached in other half of the studied patients. It is possible that some mutations were missed by WGS and WES. However, it is also possible that many of disorders in UAE population are novel and the causative mutation is not yet discovered. More researches need to be done in this population to uncover the molecular basis of these disorders.
- 5 May 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (7) , 1664-1672
KIAA1217: A novel candidate gene associated with isolated and syndromic vertebral malformations
Vertebral malformations (VMs) are caused by alterations in somitogenesis and may occur in association with other congenital anomalies. The genetic etiology of most VMs remains unknown and their identification may facilitate the development of novel therapeutic and prevention strategies. Exome sequencing was performed on both the discovery cohort of nine unrelated probands from the USA with VMs and the replication cohort from China (Deciphering Disorders Involving Scoliosis & COmorbidities study). The discovery cohort was analyzed using the PhenoDB analysis tool. Heterozygous and homozygous, rare and functional variants were selected and evaluated for their ClinVar, HGMD, OMIM, GWAS, mouse model phenotypes, and other annotations to identify the best candidates. Genes with candidate variants in three or more probands were selected. The replication cohort was analyzed by another in‐house developed pipeline. We identified rare heterozygous variants in KIAA1217 in four out of nine probands in the discovery cohort and in five out of 35 probands in the replication cohort. Collectively, we identified 11 KIAA1217 rare variants in 10 probands, three of which have not been described in gnomAD and one of which is a nonsense variant. We propose that genetic variations of KIAA1217 may contribute to the etiology of VMs.
- 5 May 2020
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 182 (7) , 1664-1672
KIAA1217: A novel candidate gene associated with isolated and syndromic vertebral malformations
Vertebral malformations (VMs) are caused by alterations in somitogenesis and may occur in association with other congenital anomalies. The genetic etiology of most VMs remains unknown and their identification may facilitate the development of novel therapeutic and prevention strategies. Exome sequencing was performed on both the discovery cohort of nine unrelated probands from the USA with VMs and the replication cohort from China (Deciphering Disorders Involving Scoliosis & COmorbidities study). The discovery cohort was analyzed using the PhenoDB analysis tool. Heterozygous and homozygous, rare and functional variants were selected and evaluated for their ClinVar, HGMD, OMIM, GWAS, mouse model phenotypes, and other annotations to identify the best candidates. Genes with candidate variants in three or more probands were selected. The replication cohort was analyzed by another in‐house developed pipeline. We identified rare heterozygous variants in KIAA1217 in four out of nine probands in the discovery cohort and in five out of 35 probands in the replication cohort. Collectively, we identified 11 KIAA1217 rare variants in 10 probands, three of which have not been described in gnomAD and one of which is a nonsense variant. We propose that genetic variations of KIAA1217 may contribute to the etiology of VMs.
- 10 July 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (10) , 2138-2143
Biallelic variants in COX4I1 associated with a novel phenotype resembling Leigh syndrome with developmental regression, intellectual disability, and seizures
Autosomal recessive COX4I1 deficiency has been previously reported in a single individual with a homozygous pathogenic variant in COX4I1, who presented with short stature, poor weight gain, dysmorphic features, and features of Fanconi anemia. COX4I1 encodes subunit 4, isoform 1 of cytochrome c oxidase. Cytochrome c oxidase is a respiratory chain enzyme that plays an important role in mitochondrial electron transport and reduces molecular oxygen to water leading to the formation of ATP. Defective production of cytochrome c oxidase leads to a variable phenotypic spectrum ranging from isolated myopathy to Leigh syndrome. Here, we describe two siblings, born to consanguineous parents, who presented with encephalopathy, developmental regression, hypotonia, pathognomonic brain imaging findings resembling Leigh‐syndrome, and a novel homozygous variant on COX4I1, expanding the known clinical phenotype associated with pathogenic variants in COX4I1.
- 10 July 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (10) , 2138-2143
Biallelic variants in COX4I1 associated with a novel phenotype resembling Leigh syndrome with developmental regression, intellectual disability, and seizures
Autosomal recessive COX4I1 deficiency has been previously reported in a single individual with a homozygous pathogenic variant in COX4I1, who presented with short stature, poor weight gain, dysmorphic features, and features of Fanconi anemia. COX4I1 encodes subunit 4, isoform 1 of cytochrome c oxidase. Cytochrome c oxidase is a respiratory chain enzyme that plays an important role in mitochondrial electron transport and reduces molecular oxygen to water leading to the formation of ATP. Defective production of cytochrome c oxidase leads to a variable phenotypic spectrum ranging from isolated myopathy to Leigh syndrome. Here, we describe two siblings, born to consanguineous parents, who presented with encephalopathy, developmental regression, hypotonia, pathognomonic brain imaging findings resembling Leigh‐syndrome, and a novel homozygous variant on COX4I1, expanding the known clinical phenotype associated with pathogenic variants in COX4I1.
- 12 March 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (6) , 1015-1019
Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy
Ethylmalonic encephalopathy (EE) is a rapidly progressive autosomal recessive mitochondrial disease caused by biallelic pathogenic variants in the ETHE1 gene that encodes the mitochondrial sulfur dioxygenase. It is characterized by neurodevelopmental delay and regression, pyramidal and extrapyramidal signs, recurrent petechiae, chronic diarrhea, and orthostatic acrocyanosis. Laboratory findings include elevated serum levels of lactate and C4‐C5 acylcarnitines, and elevated urinary excretion of ethylmalonic acid and C4‐C6 acylglycines, notably isobutyrylglycine and 2‐methylbutyrylglycine. These findings are attributed to deficiency of the mitochondrial sulfur dioxygenase resulting in toxic accumulation of hydrogen sulfide metabolites in vascular endothelium and mucosal cells of the large intestine. Medical management has thus far been directed toward decreasing the accumulation of hydrogen sulfide metabolites using a combination of metronidazole and N‐acetylcysteine. More recently, orthotopic liver transplant (OLT) has been reported as a new therapeutic option for EE. Here, we report two additional cases of EE who achieved psychomotor developmental improvement after 7‐ and 22‐months following OLT. The second case serves as the longest developmental outcome follow‐up reported, thus far, following OLT for EE. This report provides additional evidence to validate OLT as a promising therapeutic approach for what was considered to be a fatal disease.
- 12 March 2019
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 179 (6) , 1015-1019
Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy
Ethylmalonic encephalopathy (EE) is a rapidly progressive autosomal recessive mitochondrial disease caused by biallelic pathogenic variants in the ETHE1 gene that encodes the mitochondrial sulfur dioxygenase. It is characterized by neurodevelopmental delay and regression, pyramidal and extrapyramidal signs, recurrent petechiae, chronic diarrhea, and orthostatic acrocyanosis. Laboratory findings include elevated serum levels of lactate and C4‐C5 acylcarnitines, and elevated urinary excretion of ethylmalonic acid and C4‐C6 acylglycines, notably isobutyrylglycine and 2‐methylbutyrylglycine. These findings are attributed to deficiency of the mitochondrial sulfur dioxygenase resulting in toxic accumulation of hydrogen sulfide metabolites in vascular endothelium and mucosal cells of the large intestine. Medical management has thus far been directed toward decreasing the accumulation of hydrogen sulfide metabolites using a combination of metronidazole and N‐acetylcysteine. More recently, orthotopic liver transplant (OLT) has been reported as a new therapeutic option for EE. Here, we report two additional cases of EE who achieved psychomotor developmental improvement after 7‐ and 22‐months following OLT. The second case serves as the longest developmental outcome follow‐up reported, thus far, following OLT for EE. This report provides additional evidence to validate OLT as a promising therapeutic approach for what was considered to be a fatal disease.